Anthem Biosciences Limited reported impressive financial results for the first half of fiscal year 2026, showcasing a 26.3% increase in revenue compared to the same period last year. The company generated ₹10,902 million in revenue from operations, significantly up from ₹8,636 million in H1FY25. This growth was largely driven by the Custom Research and Development Manufacturing Organization (CRDMO) segment, which experienced a robust 32.3% year-over-year growth, contributing ₹9,267 million to the overall revenue. The company is set to discuss these results in detail during an earnings call on November 10, 2025, at 12:00 PM IST.

The financial results also highlighted a substantial improvement in profitability metrics. Anthem reported an EBITDA of ₹4,804 million, representing a 32.2% increase year-over-year, with EBITDA margins rising to 41.4% from 39.9% in H1FY25. Profit before tax surged to ₹4,159 million, a 31% increase, while profit after tax reached ₹3,092 million, up 26.6% year-over-year. The company's ability to control costs contributed to these positive outcomes, with a notable reduction in finance costs by 36%, along with a 55% increase in depreciation and amortization expenses.

Despite the challenges in the broader economic environment, Anthem Biosciences has positioned itself for continued growth. The company is also seeing an uptick in other income, which increased by 50.2% to ₹710 million, further bolstering its financial health. As it prepares for the upcoming earnings call, investors will be keen to hear about the strategies Anthem plans to implement to sustain this momentum and navigate the complexities of the biotechnology sector. Overall, these robust results reflect a solid operational performance and a promising outlook for Anthem Biosciences.